Established in 2013 and based in San Diego, California, U.S.A., Arcturus Therapeutics, Inc. (NASDAQ: ARCT) is a global late-stage clinical pharmaceutical company and a leading global messenger RNA (mRNA) drug and vaccines company. With proprietary technologies and expertise in (i) lipid nanoparticle-mediated drug delivery technology called LUNAR®, (ii) STARR™ mRNA technology, and (iii) mRNA drug substances and drug manufacturing, Arcturus Therapeutics is engaged in the research and development of mRNA drugs that can be effective against rare diseases such as those of the liver and respiratory tract, including vaccines for infectious diseases.

Axcelead is a group of companies engaged in developing a drug discovery platform business centered on Axcelead Drug Discovery Partners Inc. (ADDP), Japan's first drug discovery solution provider, which took over Takeda's drug discovery platform business in 2017. As of now, Axcelead has four companies under its umbrella, including ADDP and ARCALIS, and is continuing to expand its business to realize world-class drug discovery. Axcelead is the flagship portfolio company of DDG Fund, which Whiz Partners and Takeda jointly established in 2018 to promote the drug discovery ecosystem in Japan. It aims to contribute to the healthcare business in various ways in Japan and worldwide.